Autolus Therapeutics - AUTL Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings or view top-rated stocks.

3 brokers have issued 1 year target prices for Autolus Therapeutics' stock. Their AUTL share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price.
View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts.

Autolus Therapeutics' stock was trading at $1.90 at the beginning of 2023. Since then, AUTL shares have increased by 5.8% and is now trading at $2.01.
View the best growth stocks for 2023 here.

Autolus Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 500,400 shares, a decline of 24.3% from the December 31st total of 661,000 shares. Based on an average trading volume of 560,400 shares, the days-to-cover ratio is currently 0.9 days.
View Autolus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our AUTL earnings forecast.

Autolus Therapeutics plc (NASDAQ:AUTL) issued its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. The business had revenue of $2.37 million for the quarter, compared to analysts' expectations of $0.30 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Pendal Group Ltd (1.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUTL stock can currently be purchased for approximately $2.01.

Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $347.85 million and generates $2.33 million in revenue each year. The company earns $-142,100,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

The company employs 324 workers across the globe.

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.